Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Bell Potter Healthcare Conference 2025
9 slides from Proteomics International Laboratories's conference presentation, Nov 18, 2025
Slide 1: Proteomics International to present at the Bell Potter Healthcare Conference 2025
ASX release 18 November 2025 ASX code: PIQ Proteomics International to present at the Bell Potter Healthcare Conference 2025 Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ) is pleased to release a copy of the presentation to be provided by Dr Richard Lipsc
Slide 2: Bell Potter Healthcare Conference Investor Presentation: Commercial Launch
Proteomics International LABORATORIES LTD Bell Potter Healthcare Conference Investor Presentation: Commercial Launch 18-20 November 2025 Dr. Richard Lipscombe Managing Director
Slide 3: Forward Looking Statements
ASX: PIQ Forward Looking Statements This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or thei
Slide 4: Proteomics International Key Highlights
ASX: PIQ Proteomics International Key Highlights Launching four first-in-class Large addressable markets Tests validated in large diagnostics in 2025 with significant unmet clinical studies medical needs Significant advantages over current OxiDx Standards-of-Care Funded to execute Consumer driven st
Slide 5: Problem & Solution: a suite of novel diagnostic tests
ASX: PIQ Problem & Solution: a suite Targeting major diseases which are currently detected late → existing outcomes are poor for of novel diagnostic tests patients & cost healthcare system billions of dollars • A novel and accurate blood test for predicting the onset of chronic kidney disease in typ
Slide 6: Market Launch: Ramp Up → Partnering
ASX: PIQ Market Launch: Drive near-term revenue with maximum optionality for Ramp Up → Partnering strategic partnering Focus on market Grow sales via Demonstrate market awareness and strategic partnerships adoption and sales launch of tests ✓ Developed suite of highly accurate, ✓ Engagement with GP
Slide 7: Milestones: multiple value drivers achieved & ahead
ASX: PIQ Milestones: multiple value drivers achieved & ahead Q1 Q2 Q3 Q4 Milestone TARGET QTR FY25 FY26 FY26 FY26 FY26 Impact Commercial Australian clinical lab established ✓ Basis for all Promarker tests to be run clinically US reference lab established ✓ Key to first US sales and reimbursement Pro
Slide 8: Investment Summary
ASX: PIQ Investment Summary • Commercialising x4 first-in-class blood tests for major diseases and conditions with significant unmet need • Ramp-up phase for PromarkerD & PromarkerEso with first sales already achieved • Commercial platform developed to drive awareness for each test in Australia and
Slide 9: Contact
ASX:PIQ ASX: PIQ Contact Dr Richard Lipscombe Managing Director T: +61 8 9389 1992 E: enquiries@proteomicsinternational.com www.proteomicsinternational.com 8
Proteomics International Laboratories — Bell Potter Healthcare Conference 2025 on 6ix